1 |
Zirakzadeh A, Patel R. Vancomycin-resistant enterococci: colonization, infection, detection, and treatment. Mayo Clinic proceedings. Mayo Clinic 2006;81:529-36.
DOI
|
2 |
Sujatha S, Praharaj I. Glycopeptide resistance in grampositive cocci: a review. Enferm Infecc Microbiol Clin 2012;2012:781679.
|
3 |
Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002;162:2223-8.
DOI
|
4 |
Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Powe NR, Brower RG, et al. Vancomycin-sensitive and vancomycinresistant enterococcal infections in the ICU: attributable costs and outcomes. Intensive Care Med 2002;28:692-7.
DOI
|
5 |
Song X, Srinivasan A, Plaut D, Perl TM. Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs. Infect Control Hosp Epidemiol 2003;24:251-6.
DOI
|
6 |
Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348:1342-7.
DOI
|
7 |
Perichon B, Courvalin P. VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009;53:4580-7.
DOI
|
8 |
Mazuski JE. Vancomycin-resistant enterococcus: risk factors, surveillance, infections, and treatment. Surg Infect (Larchmt) 2008;9:567-71.
DOI
|
9 |
Kauffman CA. Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J Antimicrob Chemother 2003;51 Suppl 3:iii23-30.
|
10 |
Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect 2010;16:555-62.
DOI
|
11 |
Martone WJ. Spread of vancomycin-resistant enterococci: why did it happen in the United States? Infect Control Hosp Epidemiol 1998;19:539-45.
DOI
|
12 |
Uttley AH, Collins CH, Naidoo J, George RC. Vancomycinresistant enterococci. Lancet 1988;1:57-8.
|
13 |
Tenover FC, McDonald LC. Vancomycin-resistant staphylococci and enterococci: epidemiology and control. Curr Opin Infect Dis 2005;18:300-5.
DOI
|
14 |
Burrell LJ, Grabsch EA, Padiglione AA, Grayson ML. Prevalence of colonisation with vancomycin-resistant enterococci (VRE) among haemodialysis outpatients in Victoria: implications for screening. Med J Aust 2005; 182:492.
|
15 |
Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 2004;24:111-8.
DOI
|
16 |
Fisher K, Phillips C. The ecology, epidemiology and virulence of Enterococcus. Microbiology 2009;155:1749-57.
DOI
|
17 |
Muto CA, Jernigan JA, Ostrowsky BE, Richet HM, Jarvis WR, Boyce JM, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003;24:362-86.
DOI
|
18 |
Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs 2002;62:425-41.
DOI
|
19 |
Montecalvo MA. Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. J Antimicrob Chemother 2003;51 Suppl 3:iii31-5.
|
20 |
Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Infect Control Hosp Epidemiol 1995;23:87-94.
|
21 |
Yoon YK, Lee SE, Lee J, Kim HJ, Kim JY, Park DW, et al. Risk factors for prolonged carriage of vancomycin-resistant Enterococcus faecium among patients in intensive care units: a case-control study. J Antimicrob Chemother 2011;66:1831-8.
DOI
|
22 |
Baden LR, Thiemke W, Skolnik A, Chambers R, Strymish J, Gold HS, et al. Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term care patients and the significance of "clearance". Clin Infect Dis 2001;33:1654-60.
DOI
|
23 |
Henning KJ, Delencastre H, Eagan J, Boone N, Brown A, Chung M, et al. Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection. Pediatr Infect Dis J 1996;15:848-54.
DOI
|
24 |
Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev 2010;90:859-904.
DOI
ScienceOn
|
25 |
Byers KE, Anglim AM, Anneski CJ, Farr BM. Duration of colonization with vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 2002; 23:207-11.
DOI
|
26 |
Manley KJ, Fraenkel MB, Mayall BC, Power DA. Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. Med J Aust 2007;186: 454-7.
|
27 |
Szachta P, Ignys I, Cichy W. An evaluation of the ability of the probiotic strain Lactobacillus rhamnosus GG to eliminate the gastrointestinal carrier state of vancomycin-resistant enterococci in colonized children. J Clin Gastroenterol 2011;45:872-7.
DOI
|
28 |
Donskey CJ, Hoyen CK, Das SM, Helfand MS, Hecker MT. Recurrence of vancomycin-resistant Enterococcus stool colonization during antibiotic therapy. Infect Control Hosp Epidemiol 2002;23:436-40.
DOI
|
29 |
Donskey CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000;343:1925-32.
DOI
|
30 |
Harbarth S, Cosgrove S, Carmeli Y. Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimicrob Agents Chemother 2002;46: 1619-28.
DOI
|
31 |
Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995;44:1-13.
|